Ann: Imugene completes $90 M placement and launches $5 M SPP, page-73

This is incredible and places the company in a position to remain autonomous and determine its own destiny. This transaction demonstrates the commercial acumen of Paul Hopper and it must compel shareholders to vote in favour of the EGM resolution in time. This wouldn’t happen without him. This is a strategic positioning of the company especially with the buyin of biotech to lay the groundwork for a dynamic future of the company in the treatment of cancer.
Having been involved in transactional work for years it’s always fascinating to see the share drop upon immediate announcement. Lack of understanding is the issue.
Lock in those shares and watch. Bravo LC.